Michael Henderson Email and Phone Number
Michael Henderson work email
- Valid
- Valid
- Valid
Michael Henderson personal email
- Valid
- Valid
Michael Henderson phone numbers
Michael Henderson, M.D., is the CEO of Apogee Therapeutics, a biotechnology company advancing novel, potentially best-in-class therapies to address the needs of the millions of people living with immunological and inflammatory disorders.He is a proven biotechnology industry leader with expertise in business leadership, drug development, and commercial strategy. He has overseen the creation of more than 20 companies, launched 40 drug development programs, and led teams to two FDA approvals, to date. Michael received his B.A. from Harvard University and holds an M.D. from Stanford University. Originally from Oklahoma, he is a die-hard fan of the Oklahoma Sooners and a sworn enemy of any football team that opposes them.
-
Chief Executive Officer At Apogee TherapeuticsApogee Therapeutics Sep 2022 - PresentFully Remote, Us, Us
-
Chief Business OfficerBridgebio Dec 2019 - Sep 2022Palo Alto, California, Us -
Svp Of Asset Acquisition, Strategy, & OperationsBridgebio Dec 2017 - Sep 2022Palo Alto, California, Us
-
Vp Of Asset Acquisition, Strategy, & OperationsBridgebio Apr 2016 - Sep 2022Palo Alto, California, UsI lead business development, strategy and operations for BridgeBio - a biotech holding company taking a systematic approach to investment and company creation across the 7,000 monogenic diseases. We have performed 12 investments to date across oncology, dermatology, and cardio and are actively looking for new opportunities. Our typical investment size is $20M and ranges from pre-clinical to commercial.
-
CboOrigin Biosciences Jun 2018 - Sep 2022Origin Biosciences, a subsidiary of BridgeBio Pharma, is a biotechnology company focused treatment for MoCD. Origin is led by a team of veteran biotechnology executives. Together with patients and physicians, the company aims to bring a safe, effective treatment for MoCD to market as quickly as possible.
-
Member Board Of DirectorsAdrenas Therapeutics Jul 2017 - Sep 2022Adrenas is a gene-therapy company focused on a monogenic disease that presents in childhood. The company is currently in stealth mode.
-
Acting CeoQed Therapeutics Jul 2017 - Sep 2022QED Therapeutics, a subsidiary of BridgeBio Pharma, is a biotechnology company focused on precision medicine for FGFR-driven disorders. Our lead candidate is infigratinib, a best-in-class FGFR kinase inhibitor that has shown meaningful clinical activity in chemotherapy-refractory cholangiocarcinoma with FGFR2 fusions. QED is also evaluating infigratinib in preclinical studies for the treatment of achondroplasia. We plan to develop infigratinib in additional FGFR-driven tumor types and rare disorders.
-
Member Board Of DirectorsQuartz Therapeutics Sep 2016 - Sep 2022Quartz is developing compounds focused on targeted degradation of targets in the MAPK pathway. Key founding members include Frank McCormick and Robert Zamboni. The company is currently in stealth mode.
-
Member Board Of DirectorsTheras Therapeutics Sep 2016 - Sep 2022TheRas is pursuing a novel approach to drug KRAS. The technology, based on IP licensed from UCSF and being done in collaboration with the NCI RAS Initiative, is pursuing multiple approaches to targeting activated KRAS.
-
Senior AssociateMckinsey & Company Jan 2015 - Apr 2016UsAt McKinsey, I worked with leading companies in biotech and medtech across the US, EU, and Asia. My primary focus was on inorganic growth through M&A, drug discovery, and commercial strategy. -
Summer AssociateMckinsey & Company 2014 - 2014Us
-
Associate Intern - Healthcare TeamGe Ventures 2014 - 2014Completed diligence on 6 companies from Series A through Series F. Industries included neuromodulation, predictive analytics, population management, and clinical diagnostics.
-
Project ManagerKaiser Permanente Strategic Services Jul 2013 - 2014Oakland, California, UsHealthcare infrastructure buildout with focus on mobile integration. Authored multiple white-papers in areas of remote monitoring and point of care diagnostics. -
Co-FounderPellepharm Jun 2011 - 2014Founding member of pharmaceutical company developing solutions for rare diseases in the dermatology space.
-
ResearcherMassachusetts General Hospital Dec 2007 - Mar 2011Boston, Ma, UsResearch on human induced pluripotent stem cells. -
Co-Founder & Co-Editor-In-ChiefHarvard College Global Health Review Nov 2008 - Dec 2010
-
Investigative ResearcherOklahoma Medical Research Foundation May 2006 - Aug 2007Oklahoma City, Ok, UsResearch on B-cell differentiation and developing advanced MRI techniques.
Michael Henderson Education Details
-
Harvard UniversityGlobal Health -
Stanford University School Of MedicineConcentration In Health Policy
-
Stanford University Graduate School Of BusinessIgnite Program
Frequently Asked Questions about Michael Henderson
What company does Michael Henderson work for?
Michael Henderson works for Apogee Therapeutics
What is Michael Henderson's role at the current company?
Michael Henderson's current role is Chief Executive Officer at Apogee Therapeutics.
What is Michael Henderson's email address?
Michael Henderson's email address is mi****@****ail.com
What is Michael Henderson's direct phone number?
Michael Henderson's direct phone number is (650) 391*****
What schools did Michael Henderson attend?
Michael Henderson attended Harvard University, Stanford University School Of Medicine, Stanford University Graduate School Of Business.
Free Chrome Extension
Find emails, phones & company data instantly
Aero Online
Your AI prospecting assistant
Select data to include:
0 records × $0.02 per record
Download 750 million emails and 100 million phone numbers
Access emails and phone numbers of over 750 million business users. Instantly download verified profiles using 20+ filters, including location, job title, company, function, and industry.
Start your free trial